OncoSec's Visceral Lesion Applicator (VLA) Electroporation Device Demonstrates Targeted Entry and Deployment in Both Lung and Liver in Data Presented at the Society of Interventional Oncology Annual Meeting

SAN DIEGO and PENNINGTON, N.J., Feb. 3, 2020 /PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec") (Nasdaq: ONCS), a company developing late-stage intratumoral cancer immunotherapies, today announced data from a feasibility study of its visceral lesion applicator (VLA) electroporation device that were presented at the Annual Meeting of the Society of Interventional Oncology (SIO) in New Orleans.  The study, which was awarded "Best Technology Scientific Abstract" at SIO, showed investigators were able to successfully and safely reach target organs located deep inside the body and deploy the device's applicator tip in a large animal model.

In the study, titled, "Novel Electroporation Device Platform Supports Controlled Delivery of Potent Immunotherapy Directly to Target Organs," healthy animal subjects were placed under general anesthesia while investigators safely and successfully accessed and deployed the VLA in the lungs with a flexible, catheter-based applicator using a bronchoscope and a steerable catheter, and liver using ultrasound-guided laparoscopy with a rigid-trocar-based applicator.  Electroporation was performed in the liver using the APOLLO generator with no adverse effects recorded during or after electroporation.  Additionally, initial data from the APOLLO generator's built-in feedback system embedded within the platform detected and recorded trends in impedance values between different tissue types, as well as between the presence and absence of DNA.  The APOLLO generator was also able to indicate when the applicator tip was not effectively placed within the tissue.  These data highlight the safety mechanisms as well as the future possibility of differentiating between healthy tissue and a local tumor.

"These early feasibility trials are an important confirmation of our VLA platform and help to pave the way toward, initially, safety data to include in an investigational device exemption (IDE) application and eventually a Phase 1 safety trial in human subjects," said Daniel J. O'Connor, President and CEO of OncoSec.  "It is an important step toward the development of our platform as a complete and dynamic treatment system that will allow us to continue to treat cancer in internal organs utilizing the electroporation of TAVO™ (plasmid-based interleukin-12) to eliminate cancer cells."

About OncoSec Medical Incorporated 
OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer.  OncoSec has built a deep and diverse clinical pipeline utilizing its primary technology, TAVO (tavokinogene telseplasmid) as a potential treatment for multiple cancer indications either as a monotherapy or in combination with leading checkpoint inhibitors; with the latter potentially enabling OncoSec to address a great unmet medical need in oncology: anti-PD-1 non- responders.  OncoSec is also identifying and developing new DNA-encoded therapeutic candidates and tumor indications for use with its new Visceral Lesion Applicator (VLA), to target deep visceral lesions, such as liver, lung or pancreatic lesions. For more information, please visit www.oncosec.com.

TAVO is a registered trademark of OncoSec Medical Incorporated.

Forward Looking Statements
Some of the statements included in this press release may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The factors that could cause our actual results to differ materially include:  the status, progress and results of our clinical programs; our ability to obtain regulatory approvals for, and the level of market opportunity for our product candidates; our business plans, strategies and objectives, including plans to pursue collaboration, licensing or other similar arrangements or transactions; expectations regarding our liquidity and performance, including expense levels, sources of capital and ability to maintain operations as a going concern; the competitive landscape of our industry; and general market, economic and political conditions; and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.

Company Contact:
Gem Hopkins
Head of Corporate Communications
858-210-7334
ghopkins@Oncosec.com

OncoSec Medical Incorporated logo (PRNewsfoto/OncoSec Medical Incorporated)

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/oncosecs-visceral-lesion-applicator-vla-electroporation-device-demonstrates-targeted-entry-and-deployment-in-both-lung-and-liver-in-data-presented-at-the-society-of-interventional-oncology-annual-meeting-300997619.html

SOURCE OncoSec Medical Incorporated